PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022

Description: PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData expects the MenACWY patient share to remain stagnant because of the market’s high level of maturity. In contrast, the MenB vaccine market appears poised to take off in the US. GlobalData anticipates that Pfizer will target adolescents with its MenB vaccine, an approach that should facilitate rapid uptake, given the ACIP’s current immunization recommendations (CDC, 2013b). On the other hand, the reluctance of policymakers to implement a routine infant program that does not offer serogroup B protection poses a challenge to companies that have targeted this age segment, such as GSK.

Scope

- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Meningococcal Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US

Contents:

1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Meningococcal Immunization Policy
4.2 US
4.2.1 Meningococcal Immunization Recommendations and Policies
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles – Major Brands
5.3.1 Menactra
5.3.2 Menevo
5.3.3 MenHibrix
5.3.4 Menomune
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Unmet Need: Protection Against Serogroup B Disease
6.2.2 Unmet Need: A Pentavalent (MenABCWY) Vaccine
6.2.3 Unmet Need: More Cost-Effective Vaccines
6.2.4 Unmet Need: Improved Duration of Immunity in Children and Adolescents
6.2.5 Unmet Need: Immunogenic Infant Vaccines
6.2.6 Unmet Need: Improved Vaccination Coverage Rates
6.2.7 Unmet Need: Increased Patient Awareness and Education
6.3 Unmet Needs Gap Analysis
6.4 Opportunities
6.4.1 Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations
6.4.2 Opportunity: Improving Immune Response Duration with Adjuvants
6.4.3 Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets
7 Pipeline Assessment
7.1 Overview
7.2 Promising Vaccines in Clinical Development
7.2.1 MnB rLP2086
7.3 Promising Vaccines in Early Clinical Development
8 Market Outlook
8.1 United States
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Vaccine Coverage
9.4.2 Vaccine Approval vs. Routine Schedule Inclusion
9.4.3 Vaccines Included
9.4.4 Key Launch Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Vaccine Assumptions
9.4.7 Pricing of Pipeline agents
9.5 Physicians and Specialists Included in this Study
9.6 About the Authors
9.6.1 Authors
9.6.2 Reviewers
9.6.3 Global Head of Healthcare
9.7 About Us
9.8 Disclaimer

1.1 List of Tables
Table 1: Symptoms of Meningococcal Disease
Table 2: Meningococcal Immunization Recommendation Agencies by Country
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012
Table 4: Leading Vaccines for Meningococcal Disease, 2012
Table 5: Product Profile – Menactra
Table 6: Menactra SWOT Analysis, 2012
Table 7: Product Profile – Menveo
Table 8: Menveo SWOT Analysis, 2012
Table 9: Product Profile – MenHibrix
Table 10: MenHibrix SWOT Analysis, 2012
Table 11: Product Profile – Menomune
Table 12: Menomune SWOT Analysis, 2012
Table 13: Overall Unmet Needs – Current Level of Attainment
Table 14: Clinical Unmet Needs – Gap Analysis, 2012
Table 15: Meningococcal Vaccines – Phase Pipeline, 2012
Table 16: Comparison of Vaccines in Development for Meningococcal Disease, 2012
Table 17: Product Profile – MnB rLP2086
Table 18: MnB rLP2086 SWOT Analysis, 2012
Table 19: Sales Forecasts ($m) for Meningococcal Vaccines in the United States, 2012–2022
Table 20: Key Events Impacting Sales for Meningococcal Vaccines in US, 2012
Table 21: United States Meningococcal Vaccines Market – Drivers and Barriers, 2012–2022
Table 22: Key Launch Dates
Table 23: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Membrane Structure of N. meningitidis
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Meningococcal Vaccines, 2012–2022
Figure 3: Sales for Meningococcal Vaccines in the United States by Vaccine Class, 2012–2022

Ordering:  
Order Online - [http://www.researchandmarkets.com/reports/2588297/](http://www.researchandmarkets.com/reports/2588297/)
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit [http://www.researchandmarkets.com/contact/](http://www.researchandmarkets.com/contact/)

Order Information
Please verify that the product information is correct and select the format(s) you require.

**Product Name:** PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022
**Web Address:** [http://www.researchandmarkets.com/reports/2588297/](http://www.researchandmarkets.com/reports/2588297/)
**Office Code:** SCBR37L2

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 9990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td></td>
</tr>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ___________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World